Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diethylpropion. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.41 |
| ▸ | PGR | P06401 | 1/20 | 0.96 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.96 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.96 |
| ▸ | HTR2A | P28223 | 1/20 | 0.96 |
| ▸ | HRH1 | P35367 | 1/20 | 0.96 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.96 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diethylpropion SCHEMBL7715371 | 1.00 | PGR (0.96) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL22614735 | 1.00 | PGR (0.96) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL15483 | 1.00 | PGR (0.96) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL18141848 | 0.98 | PGR (0.93) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL5244701 | 0.98 | PGR (0.93) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL5546846 | 0.98 | PGR (0.93) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL9101119 | 0.98 | PGR (0.93) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL27330 | 0.98 | PGR (1.00) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL15484 | 0.98 | PGR (1.00) | PGRADRA2AADRA2BHTR2AHRH1 | |
| Diethylpropion SCHEMBL3051269 | 0.95 | PGR (0.93) | PGRADRA2AADRA2BHTR2AHRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130217749-A1 | MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION | YALE UNIVERSITY (US) | 2013-08-22 | — | — | US | claimed |
| WO-2010090830-A1 | MODULATION OF SIRT1 EXPRESSION | ISIS PHARMACEUTICALS, INC. (US) | 2010-08-12 | — | — | WO | claimed |
| US-RE48060-E1 | Antisense modulation of PTP1B expression | IONIS PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| EP-3401401-B1 | ANTISENSE MODULATION OF GCGR EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2020-04-15 | — | — | EP | disclosed |
| EP-3401401-A1 | ANTISENSE MODULATION OF GCGR EXPRESSION | Ionis Pharmaceuticals, Inc. (US) | 2018-11-14 | — | — | EP | disclosed |
| EP-2758533-B1 | ANTISENSE MODULATION OF GCGR EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2018-04-11 | — | — | EP | disclosed |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-08-03 | — | — | US | disclosed |
| US-9682093-B2 | Compositions and methods for treating or preventing metabolic syndrome disorders | CHARLES R. DREW UNIVERSITY OF MEDICINE AND SCIENCE (US) | 2017-06-20 | — | — | US | disclosed |
| EP-2697244-B1 | ANTISENSE MODULATION OF PTP1B EXPRESSION | IONIS PHARMACEUTICALS INC (US) | 2017-05-17 | — | — | EP | disclosed |
| US-9597347-B2 | Compositions for treating obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2017-03-21 | — | — | US | disclosed |
| US-9567587-B2 | Antisense modulation of GCCR expression | IONIS PHARMACEUTICALS, INC. (US) | 2017-02-14 | — | — | US | disclosed |
| EP-1898897-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | Sirtris Pharmaceuticals, Inc. (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRTRIS PHARMACEUTICALS, INC. | 2007-06-28 | — | — | US | disclosed |
| WO-2007008548-A2 | METHODS AND RELATED COMPOSITIONS FOR TREATING OR PREVENTING OBESITY, INSULIN RESISTANCE DISORDERS, AND MITOCHONDRIAL-ASSOCIATED DISORDERS | SIRTRIS PHARMACEUTICALS, INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| WO-2007005453-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-01-11 | — | — | WO | disclosed |
| EP-1708689-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | The President and Fellows of Harvard College (US) | 2006-10-11 | — | — | EP | disclosed |
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2006-05-25 | — | — | US | disclosed |
| WO-2005100382-A1 | VERTEBRATE PEPTIDE MODULATORS OF LIPID METABOLISM | BLM GROUP, INC. (US) | 2005-10-27 | — | — | WO | disclosed |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-08-04 | — | — | US | disclosed |
| WO-2005065667-A2 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2005-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111435-A1 | Contacting cells with sirtuin activator or inhibitor; increasing or decreasing fat accumulation | FABP4, PLIN1, SIRT1 | SLC6A2 4478/4885SLC6A3 4525/4885PGR 4452/4885 |
| US-20130217749-A1 | MODULATION OF PHOSPHOENOLPYRUVATE CARBOXYKINASE-MITCHONDRIAL (PEPCK-M) EXPRESSION | PCK2, PCK1, PC | SLC6A2 4684/4885SLC6A3 4686/4885PGR 4473/4885 |
| US-20170216272-A1 | COMPOSITIONS FOR TREATING OR PREVENTING OBESITY AND INSULIN RESISTANCE DISORDERS | FABP4, GPR119, SIRT1 | SLC6A2 4088/4885SLC6A3 3705/4885PGR 3636/4885 |
| US-20070149466-A1 | Methods and related compositions for treating or preventing obesity, insulin resistance disorders, and mitochondrial-associated disorders | SIRT1, SIRT3, SIRT2 | SLC6A2 2586/4885SLC6A3 4005/4885PGR 2495/4885 |
| US-20050171027-A1 | Compositions for treating or preventing obesity and insulin resistance disorders | FABP4, GPR119, SIRT1 | SLC6A2 4088/4885SLC6A3 3705/4885PGR 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.